{
    "organizations": [],
    "uuid": "dc40b59a4e6294de876d9f707b64e4740a5c874b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-biohaven-announces-license-agreeme/brief-biohaven-announces-license-agreement-with-catalent-for-zydis-odt-with-small-molecule-cgrp-receptor-antagonists-idUSFWN1QB06R",
    "ord_in_thread": 0,
    "title": "BRIEF-Biohaven Announces License Agreement With Catalent For Zydis ODT With Small Molecule Cgrp Receptor Antagonists",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 21, 2018 / 8:09 AM / Updated 9 minutes ago BRIEF-Biohaven Announces License Agreement With Catalent For Zydis ODT With Small Molecule Cgrp Receptor Antagonists Reuters Staff 1 Min Read Feb 21 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd: * BIOHAVEN ANNOUNCES EXCLUSIVE LICENSE WITH CATALENT FOR ZYDIS® ORALLY DISSOLVING TABLET WITH SMALL MOLECULE CGRP RECEPTOR ANTAGONISTS * ENTERED LICENSE AGREEMENT CATALENT U.K. SWINDON ZYDIS LTD TO PROVIDE CATALENT‘S ZYDIS ODT FAST-DISSOLVING FORMULATION * AGREEMENT FOR DEVELOPMENT OF BIOHAVEN‘S LEAD CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST PRODUCT CANDIDATE, RIMEGEPANT * AGREEMENT ALSO PROVIDES EXCLUSIVE RIGHTS FOR DEVELOPING SMALL MOLECULE CGRP RECEPTOR ANTAGONISTS WITH ZYDIS ODT TECHNOLOGY Source text for Eikon: Further company coverage: (Bengaluru Newsroom)",
    "published": "2018-02-21T10:06:00.000+02:00",
    "crawled": "2018-02-21T10:22:59.054+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "updated",
        "minute",
        "ago",
        "announces",
        "license",
        "agreement",
        "catalent",
        "zydis",
        "odt",
        "small",
        "molecule",
        "cgrp",
        "receptor",
        "antagonist",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "biohaven",
        "pharmaceutical",
        "holding",
        "company",
        "ltd",
        "biohaven",
        "announces",
        "exclusive",
        "license",
        "catalent",
        "orally",
        "dissolving",
        "tablet",
        "small",
        "molecule",
        "cgrp",
        "receptor",
        "antagonist",
        "entered",
        "license",
        "agreement",
        "catalent",
        "swindon",
        "zydis",
        "ltd",
        "provide",
        "catalent",
        "zydis",
        "odt",
        "formulation",
        "agreement",
        "development",
        "biohaven",
        "lead",
        "calcitonin",
        "peptide",
        "receptor",
        "antagonist",
        "product",
        "candidate",
        "rimegepant",
        "agreement",
        "also",
        "provides",
        "exclusive",
        "right",
        "developing",
        "small",
        "molecule",
        "cgrp",
        "receptor",
        "antagonist",
        "zydis",
        "odt",
        "technology",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "bengaluru",
        "newsroom"
    ]
}